Catumaxomab (trade name Removab) is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with...
8 KB (709 words) - 20:33, 1 December 2023
T cell/cancer cell interactions using label-free live cell imaging. Catumaxomab, one of the first trifunctional antibodies approved for therapeutic use...
29 KB (3,349 words) - 19:04, 30 July 2024
cells from malignant ascites fluid were eliminated due to catumaxomab treatment. Catumaxomab, was the first to be approved for clinical use (in 2009 for...
12 KB (1,444 words) - 07:52, 29 April 2024
promising results in clinical trials. In April 2009, the bispecific antibody catumaxomab was approved in the European Union. Since 2000, the therapeutic market...
57 KB (4,072 words) - 11:12, 5 August 2024
oncology/immune indications Carotuximab mab chimeric endoglin angiosarcoma Catumaxomab Removab 3funct rat/mouse hybrid EpCAM, CD3 Y ovarian cancer, malignant...
136 KB (4,020 words) - 07:14, 15 August 2024
Lordick, F.; Ott, K.; Weitz, J.; Jäger, D. (2008). "The evolving role of catumaxomab in gastric cancer". Expert Opinion on Biological Therapy. 8 (9): 1407–15...
38 KB (3,088 words) - 05:02, 8 August 2024
Trastuzumab emtansine Trastuzumab deruxtecan) Others for solid tumors EpCAM (Catumaxomab Edrecolomab) VEGF-A (Bevacizumab) Leukemia/lymphoma lymphoid: CD3 (Glofitamab...
12 KB (794 words) - 03:30, 2 September 2024
Trastuzumab emtansine Trastuzumab deruxtecan) Others for solid tumors EpCAM (Catumaxomab Edrecolomab) VEGF-A (Bevacizumab) Leukemia/lymphoma lymphoid: CD3 (Glofitamab...
12 KB (758 words) - 23:46, 14 March 2024
Catapres-TTS Catarase Cathflo Activase cathine (INN) cathinone (INN) Catiolanze catramilast (USAN, INN) catridecacog (INN) catumaxomab (INN) Caverject Cayston...
16 KB (757 words) - 05:06, 19 June 2024
Ramucirumab L01FX01 Edrecolomab L01FX02 Gemtuzumab ozogamicin L01FX03 Catumaxomab L01FX04 Ipilimumab L01FX05 Brentuximab vedotin L01FX06 Dinutuximab beta...
12 KB (877 words) - 15:36, 25 January 2024
EpCAM itself may be a target for therapeutic intervention. Edrecolomab, catumaxomab, nofetumomab and other monoclonal antibodies are designed to bind to...
20 KB (2,451 words) - 12:05, 4 April 2024
development plans. (So they could concentrate on their other product catumaxomab (trade name Removab).: 35 ) Fresenius ClinicalTrials.gov: Phase II Study...
2 KB (118 words) - 04:19, 3 April 2023
vedotin§ Vanucizumab§ Veltuzumab§ Vorsetuzumab mafodotin§ Rat/mouse hybrid Catumaxomab Ertumaxomab§ Chimeric + humanized Depatuxizumab mafodotin† Duvortuxizumab...
3 KB (129 words) - 01:04, 19 July 2023
vedotin§ Vanucizumab§ Veltuzumab§ Vorsetuzumab mafodotin§ Rat/mouse hybrid Catumaxomab Ertumaxomab§ Chimeric + humanized Depatuxizumab mafodotin† Duvortuxizumab...
5 KB (368 words) - 15:29, 21 August 2024
vedotin§ Vanucizumab§ Veltuzumab§ Vorsetuzumab mafodotin§ Rat/mouse hybrid Catumaxomab Ertumaxomab§ Chimeric + humanized Depatuxizumab mafodotin† Duvortuxizumab...
4 KB (241 words) - 13:42, 14 July 2024